Novo and Novartis funds back $16m Series A for US dermatology startup Thesan
This article was originally published in Scrip
Executive Summary
Two pharma-backed venture investment firms put $16 million into a Series A round for a new Southern California dermatology drug company called Thesan Pharmaceuticals, which is run by Gordon Foulkes - the former CEO of San Diego startup Excaliard Pharmaceuticals that Pfizer acquired in 2011 (scripintelligence.com, 23 November 2011).